ScholarX: Browsing ScholarWorks

Browsing by Huddart, RA[Huddart, Robert A.]Author

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

전체 가 나 다 라 마 바 사 아 자 차 카 타 파 하

Sort by: In order: Results/Page Authors/Record:

Showing results 1 to 5 of 5

SCIESCOPUS

Erdafitinib (ERDA; JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRa): Phase 2 continuous versus intermittent dosing.

Loriot, Y[Loriot, Yohann]; Necchi, A[Necchi, Andrea]; Park, SH[Park, Se Hoon]; Garcia-Donas, J[Garcia-Donas, Jesus]; Huddart, RA[Huddart, Robert A.]; Burgess, EF[Burgess, Earle Frederick]; Fleming, MT[Fleming, Mark T.]; Rezazadeh, A[Rezazadeh, Arash]; Mellado, B[Mellado, Begona]; Varlamov, S[Varlamov, Sergei], et al.

ArticleIssue Date2018CitationJOURNAL OF CLINICAL ONCOLOGY, v.36, no.6PublisherAMER SOC CLINICAL ONCOLOGY

SCIESCOPUS

ERDAFITINIB in locally advanced or metastatic urothelial carcinoma (mUC): Long-term outcomes in BLC2001.

Siefker-Radtke, AO[Siefker-Radtke, Arlene O.]; Necchi, A[Necchi, Andrea]; Park, SH[Park, Se Hoon]; Garcia-Donas, J[Garcia-Donas, Jesus]; Huddart, RA[Huddart, Robert A.]; Burgess, EF[Burgess, Earle Frederick]; Fleming, MT[Fleming, Mark T.]; Rezazadeh, A[Rezazadeh, Arash]; Mellado, B[Mellado, Begona]; Varlamov, S[Varlamov, Sergei], et al.

ArticleIssue Date2020CitationJOURNAL OF CLINICAL ONCOLOGY, v.38, no.15PublisherAMER SOC CLINICAL ONCOLOGY

SCIESCOPUS

First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt).

Siefker-Radtke, AO[Siefker-Radtke, Arlene O.]; Necchi, A[Necchi, Andrea]; Park, SH[Park, Se Hoon]; GarcAa-Donas, J[GarcAa-Donas, JesAs]; Huddart, RA[Huddart, Robert A.]; Burgess, EF[Burgess, Earle Frederick]; Fleming, MT[Fleming, Mark T.]; Rezazadeh, A[Rezazadeh, Arash]; Mellado, B[Mellado, Begona]; Varlamov, S[Varlamov, Sergei], et al.

ArticleIssue Date2018CitationJOURNAL OF CLINICAL ONCOLOGY, v.36, no.15PublisherAMER SOC CLINICAL ONCOLOGY

SCIESCOPUS

Management of fibroblast growth factor receptor inhibitor (FGFRi) treatment-emergent adverse events (TEAEs) of interest in patients (Pts) with locally advanced or metastatic urothelial carcinoma (mUC).

Siefker-Radtke, AO[Siefker-Radtke, Arlene O.]; Necchi, A[Necchi, Andrea]; Park, SH[Park, Se Hoon]; Garcia-Donas, J[Garcia-Donas, Jesus]; Huddart, RA[Huddart, Robert A.]; Burgess, EF[Burgess, Earle F.]; Fleming, MT[Fleming, Mark T.]; Rezazadeh, A[Rezazadeh, Arash]; Mellado, B[Mellado, Begona]; Varlamov, S[Varlamov, Sergei], et al.

ArticleIssue Date2021CitationJOURNAL OF CLINICAL ONCOLOGY, v.39, no.6PublisherLIPPINCOTT WILLIAMS & WILKINS

SCIESCOPUS

Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt)

Loriot, Y[Loriot, Yohann]; Matsubara, N[Matsubara, Nobuaki]; Park, SH[Park, Se Hoon]; Huddart, RA[Huddart, Robert A.]; Burgess, EF[Burgess, Earle F.]; Houede, N[Houede, Nadine]; Banek, S[Banek, Severine]; Laguerre, B[Laguerre, Brigitte]; Guadalupi, V[Guadalupi, Valentina]; Ku, JH[Ku, Ja Hyeon], et al.

ArticleIssue Date2023CitationJOURNAL OF CLINICAL ONCOLOGY, v.41, no.17PublisherLIPPINCOTT WILLIAMS & WILKINS

STATISTICS: Total View:; Daily View:

RSS_1.0 RSS_2.0 ATOM_1.0

(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREA samsunglib@skku.edu

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Browsing by Huddart, RA[Huddart, Robert A.]Author

BROWSE